Exhibit 99.1

INTERNATIONAL GAME TECHNOLOGY PLC

Notice of Annual General Meeting 2025

Tuesday, 13 May 2025 at 3.00 p.m. (BST)

Notice of the annual general meeting of International Game Technology PLC, to be held at the registered office of the Company at 3rd Floor 10 Finsbury Square, London, England, EC2A 1AF on 13 May 2025 at 3.00 p.m. (BST), is set out in this document.

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about its contents or the action you should take in relation to it, you should consult your stockbroker, solicitor, accountant or other professional advisor.

If you have sold or transferred all your ordinary shares in International Game Technology PLC, please pass this document and its accompanying documents as soon as possible to the purchaser or transferee, or to the stockbroker or other agent through whom you made the sale or transfer so that they can pass them to the person who now holds the shares.

International Game Technology PLC

Registered office: 3rd Floor 10 Finsbury Square, London, England, EC2A 1AF

Registered in England and Wales with company number 09127533

Chairperson’s letter

International Game Technology PLC will hold its 2025 annual general meeting at the registered office of the Company at 3rd Floor 10 Finsbury Square, London, England, EC2A 1AF on 13 May 2025 at 3.00 p.m. (BST). Instructions on how to get to the venue are available on page 1 of this document.

Notice of Annual General Meeting

Notice is hereby given that the annual general meeting of International Game Technology PLC (the “Company”) will be held at the registered office of the Company at 3rd Floor 10 Finsbury Square, London, England, EC2A 1AF on 13 May 2025 at 3.00 p.m. (BST) (the “AGM”), to consider and, if thought fit, pass the following resolutions.

Resolutions 1 to 18 (inclusive) and Resolution 21 will be proposed as ordinary resolutions. For each of those resolutions to be passed, more than 50% of the votes cast must be in favour of the resolution. Resolutions 19 and 20 will be proposed as special resolutions. For each of those resolutions to be passed, at least 75% of the votes cast must be in favour of the resolution.

Ordinary resolution: Annual Report and Accounts

Ordinary resolution: Directors’ remuneration report

Ordinary resolution: Continued appointment of directors

Ordinary resolution: Re-appointment of auditors

Ordinary resolution: Remuneration of auditors

Ordinary resolution: Political donations

in each case, as such terms are defined in Part 14 of the Act and provided that the aggregate of all expenditure under paragraphs 17.1, 17.2 and 17.3 of this Resolution 17 during the period commencing on the date of the passing of this resolution and ending at the earlier of the conclusion of the Company’s next annual general meeting or, if sooner, 12 August 2026, shall not exceed £100,000 (or its equivalent in another currency) in total.

Ordinary resolution: Authority to allot shares

shares, record dates or any legal, regulatory or practical problems in or under the laws of any territory, or the requirements of any regulatory body or stock exchange or any other matter; and

for a period expiring (unless previously revoked, varied or renewed) at the end of the next annual general meeting of the Company or, if sooner, on 12 August 2026, but in each case the Company may, before such expiry, make an offer or agreement which would or might require Relevant Securities or special voting shares (as applicable) to be allotted after this authority expires and the directors may allot Relevant Securities or special voting shares (as applicable) in pursuance of such offer or agreement as if this authority had not expired.

This authority is in substitution for all previous unutilised authorities given to the directors pursuant to section 551 of the Act, save to the extent that those authorities are exercisable pursuant to section 551(7) of the Act by reason of any offer or agreement made prior to the date of this resolution which would or might require shares to be allotted or rights to be granted on or after that date.

Special resolution: Disapplication of pre-emption rights

but the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after this power expires and the directors may allot equity securities in pursuance of such offer or agreement as if this power had not expired.

This power is in substitution for all previous unutilised powers given to the directors pursuant to section 570 and section 573 of the Act, save to the extent that those powers are exercisable pursuant to section 570(4) and section 573(3) of the Act by reason of any offer or agreement made prior to the date of the resolution which would or might require equity securities to be allotted on or after that date.

This power applies in relation to a sale of treasury shares which is an allotment of securities by virtue of section 560(3) of the Act as if in the first paragraph of this resolution the words “pursuant to the authority conferred by Resolution 18” were omitted.

provided that this power shall expire (unless previously revoked, varied or renewed) at the end of the next annual general meeting of the Company or, if sooner, on 12 August 2026, but the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after this power expires and the directors may allot equity securities in pursuance of such offer or agreement as if this power had not expired.

This power applies in relation to a sale of treasury shares which is an allotment of equity securities by virtue of section 560(3) of the Act as if in the first paragraph of this resolution the words “pursuant to the authority conferred by Resolution 18” were omitted.

Ordinary resolution: Company’s authority to purchase its own shares

By order of the Board

Pierfrancesco Boccia

Company Secretary

3 April 2025

Registered office:

3rd Floor 10 Finsbury Square

London EC2A 1AF

England

Registered in England and Wales with company number 09127533

Explanatory notes to the resolutions

The business of the meeting is set out in the resolutions on pages 4 to 7. The purpose of each resolution is explained below.

Resolution 1

Annual Report and Accounts

The Act requires that the directors of the Company lay the Annual Report and Accounts before the Company in general meeting. The Board asks that shareholders receive and adopt the Annual Report and Accounts which were published and made available to shareholders together with this Notice of AGM.

Resolution 2

Directors’ remuneration report

The Board must put a resolution to shareholders at the AGM of the Company to approve the directors’ remuneration report (other than the part relating to the directors’ remuneration policy), which forms part of the Annual Report and Accounts. As in previous years, this resolution is advisory in nature and the directors’ entitlement to remuneration is not conditional on the resolution being passed.

The Company’s auditors for the financial year ended 31 December 2024 have audited those parts of the directors’ remuneration report that are required to be audited and their report relating to the directors’ remuneration report can be found in the Annual Report and Accounts.

The directors’ remuneration policy was approved by shareholders at the annual general meeting held on 14 May 2024 and is therefore not required to be put to shareholders for approval at this year’s meeting. In accordance with the Act, it will be put to shareholders for approval again no later than at the annual general meeting in 2027. The full remuneration policy can be found in the Annual Report and Accounts (pages 65 to 75), as well as the annual report and accounts for the financial year ended 31 December 2023 (pages 69 to 82) available at the “Investor Relations” section of the Company’s website (www.igt.com).

Resolutions 3 to 14

Continued appointment of existing directors

The Board currently has 12 directors (comprising an Executive Chair (who is an executive director), a Lead Independent Director (who is also Vice Chair and a non-executive director), two other executive directors and eight other non-executive directors), whose experience and expertise are derived from a range of industries, sectors and who possess personal characteristics that provide an invaluable and diverse perspective on the Company’s business.

Each of the directors then in office underwent the Company’s customary annual performance evaluation in November 2024. In February 2025, the Board (with the support of the nominating and corporate governance committee of the Board) reviewed and was satisfied with the size and composition of the Board and its committees. Having assessed the outcome of the November 2024 evaluation and subsequent review in February 2025, the Board is satisfied that each director remains committed to the role and their performance continues to be effective. The Board is also satisfied that each of the independent non-executive directors remains independent in both character and judgement and that there are no relationships or circumstances likely to affect their independence.

In the interests of good corporate governance, the Board determines that it is in the best interests of the Company and its shareholders as a whole to put forward the directors for a shareholder vote to approve their continued appointment as directors of the Company. Members should vote on the continued appointment of all directors and these resolutions therefore seek shareholder approval for the continued appointment of these individuals, each such person having confirmed their willingness to continue in office.

Full biographical details of the individuals whose continuing appointment as directors of the Company is to be approved, including their professional experience, education and professional credentials, can be found in the

Annual Report and Accounts (Directors’ Report – Governance) accompanying this document (pages 50 to 53) and on the Company’s website (ir.igt.com/esg/board-of-directors).

Resolutions 15 and 16

Re-appointment and remuneration of auditors

The Company has to appoint the auditors at each general meeting at which its accounts are presented, to hold office until the end of the next meeting of that type. Pursuant to Resolution 15, the Board proposes the re-appointment of PricewaterhouseCoopers LLP as the Company’s auditors to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting at which the annual report and accounts are laid before the Company.

Resolution 16 follows best practice in corporate governance by separately seeking authority for the Board or its audit committee to determine the auditors’ remuneration.

Resolution 17

Political donations and expenditure

The Act requires shareholder approval for donations by companies to political parties or other political organisations, or any political expenditure. The Act defines donation in this context very broadly, as a result of which the relevant legislative provisions might catch activities that form part of normal business relationships and engagement by the Company with key interested parties and stakeholders which, in each case, it is in the Company’s interests and the interests of shareholders to support.

The Company’s policy is not to make political donations or incur political expenditure as those expressions are normally understood. This resolution is therefore proposed on a precautionary basis only, to ensure that neither the Company nor any of its subsidiaries commit a technical breach that could arise from the uncertainty generated by the broad definitions contained within the Act.

The authority conferred by Resolution 17 will expire at the end of the next annual general meeting or, if sooner, on 12 August 2026.

Resolution 18

Authority to allot shares

Under the Act, the directors may allot shares (or grant certain rights over shares) only if they are authorised to do so by the Company’s articles of association or with the authority of shareholders in a general meeting (other than pursuant to an employee share scheme within the meaning of the Act).

Resolution 18, which will be proposed as an ordinary resolution, renews the directors’ authority to allot shares which was granted at the 2024 annual general meeting.

Paragraphs 18.1 and 18.2 of Resolution 18 authorise the directors to allot ordinary shares up to a maximum nominal amount of US$6,734,431.40 and up to a further maximum nominal amount of US$6,734,431.40 where the allotment is in connection with an offer by way of a rights issue, in each case representing approximately one third of the nominal value of the Company’s issued ordinary share capital (excluding treasury shares) on 25 March 2025. These limits are in accordance with guidelines issued by the Investment Association.

In addition, paragraph 18.3 of Resolution 18 authorises the directors to allot special voting shares up to a maximum nominal amount of US$134.70. This authority is required because the Company’s articles of association stipulate that, if there is an allotment of ordinary shares, then there must also be a simultaneous allotment of special voting shares, so that the aggregate number of ordinary shares in issue is equal to the aggregate number of special voting shares in issue.

The directors have no current intention of exercising the authorities sought in paragraphs 18.1 and 18.2 of Resolution 18, other than pursuant to the Company’s equity incentive plan reserved for employees and directors of the Company and its subsidiaries. However, the directors believe it to be in the best interests of the Company

to maintain the flexibility that these authorities provide. If the directors do exercise these authorities, the directors intend to follow best practices as regards their use, as recommended by the Investment Association.

The directors have no intention of exercising the authority sought in paragraph 18.3 of Resolution 18 other than in conjunction with an issue of ordinary shares, to ensure compliance with the requirement in the Company’s articles of association as noted above.

The authority conferred by Resolution 18 will expire at the end of the next annual general meeting or, if sooner, on 12 August 2026.

Resolutions 19 and 20

Disapplication of pre-emption rights

Directors wishing to allot any ordinary shares, grant rights over ordinary shares, or sell ordinary shares held in treasury, in each case for cash (other than pursuant to an employee share scheme within the meaning of the Act), must first offer them to existing shareholders in proportion to their existing holdings. These are known as pre-emption rights. The special voting shares are not subject to these pre-emption rights, because they do not qualify as “equity securities” for the purposes of section 560 of the Act.

Resolutions 19 and 20, which will be proposed as special resolutions, are intended to renew the disapplication of these statutory pre-emption rights which were granted at the 2024 annual general meeting.

Resolutions 19 and 20 will give the directors power to allot ordinary shares without the application of statutory pre-emption rights: first, in relation to offers of equity securities by way of rights issue, open offer or similar arrangements (save that, in the case of an allotment pursuant to the authority conferred by paragraph 18.2 of Resolution 18, such offer shall be by way of rights issue only); second, in relation to the allotment of equity securities for cash up to a maximum aggregate nominal amount of US$2,020,329.40 (representing approximately 10% of the nominal value of the Company’s issued ordinary share capital (excluding treasury shares) on 25 March 2025); and third, in relation to an acquisition or other capital investment as defined by the Pre-emption Group’s Statement of Principles (the “Principles”), an additional aggregate nominal amount of US$2,020,329.40 (also representing approximately 10% of the nominal value of the Company’s issued ordinary share capital (excluding treasury shares) on 25 March 2025). These limits are in accordance with guidelines issued by the Pre-emption Group and the Investment Association.

The directors have no current intention of exercising these powers, other than pursuant to the Company’s equity incentive plan reserved for employees and directors of the Company and its subsidiaries. However, in certain circumstances, it may be in the best interests of the Company to allot shares for cash or grant rights over shares (other than pursuant to an employee share scheme within the meaning of the Act) without first offering them proportionately to existing shareholders, and the powers in Resolutions 19 and 20 give the directors flexibility to take advantage of business opportunities that may arise.

Where applicable and to the extent reasonably practicable and permitted by law, the directors intend to adhere to the provisions in the Principles when exercising the authority to allot shares for cash on a non pre-emptive basis pursuant to the power in Resolution 19 or Resolution 20.

The powers sought and limits set by these resolutions will also apply to a sale by the Company of any shares it holds as treasury shares.

The authority conferred by these resolutions will expire at the end of the next annual general meeting or, if sooner, on 12 August 2026.

Resolution 21

Company’s authority to purchase its own shares

As the Company is an English public limited company that has its ordinary shares listed only on the NYSE, under the Act, the Company may only conduct repurchases of its ordinary shares in accordance with specific procedures for “off-market” purchases of such shares. As such, these repurchases may only be made pursuant to a form of

share repurchase contract, the terms of and counterparties to which have been approved by the Company’s shareholders in accordance with section 694 of the Act.

Resolution 21, which will be proposed as an ordinary resolution, renews the Company’s authority to purchase its own shares which was granted at the 2024 annual general meeting. Resolution 21 will authorise the Company to purchase up to 30,302,921 ordinary shares, representing approximately (but not exceeding) 15% of the Company’s issued ordinary share capital (excluding treasury shares) on 25 March 2025. In line with the authorization granted at the 2024 annual general meeting, the Company may make repurchases in pursuance of a contract concluded before the expiry of the 2025 annual general meeting authorization which will be completed or executed partly after such expiry.

The Company is also seeking approval of the forms of share repurchase contract, the terms of and counterparties pursuant to which the Company may conduct the purchase of its ordinary shares. The share repurchases may only be effected through off-market share purchases, including (i) pursuant to Rule 10b5-1 and/or Rule 10b-18 plans; (ii) by way of accelerated share repurchase programs; and (iii) by way of tender offers.

Rule 10b5-1 and/or Rule 10b-18 plans

The five sets of Rule 10b5-1 and Rule 10b-18 share repurchase contracts, each consisting of a “Rule 10b-18 Repurchase Contract” and a “Rule 10b5-1 Repurchase Plan”, are substantially in the same form approved by shareholders at the 2024 annual general meeting. Purchases will be in accordance with Rule 10b-18 of the Securities Exchange Act 1934 (the “Exchange Act”).

The maximum price that shall be paid to purchase each ordinary share is 105% of the average market value of an ordinary share for the five business days prior to the day the purchase is made (subject to any further price restrictions contained in any such share repurchase contract).

Accelerated share repurchase (“ASR”)

Pursuant to the ASR agreement, the Company will purchase its ordinary shares from one or more investment banks on an accelerated and structured basis and at a price or prices as provided therein and subject to any adjustments as provided for therein. In an ASR transaction, the counterparty borrows a substantial portion of the total number of shares expected to be repurchased by the Company thereunder for initial delivery to the Company at the beginning of the ASR’s term. The final number of shares to be deliverable to the Company will be determined at the final settlement date at the end of the ASR term. The Company’s per share repurchase price will be based on a measure of the volume weighted average market price of the shares during the ASR term. The ASR transaction will be documented as an equity derivative transaction under a “long-form” ISDA-based confirmation (which may include component master and supplemental confirmations and will incorporate terms from an ISDA master agreement and ISDA-published definitions) specifically governing the ASR transaction.

Tender offer

Pursuant to the option framework agreement, the counterparty will purchase, as principal, from shareholders of the Company shares tendered in one or more tender offers. The counterparty has the right to require the Company to purchase the tendered shares from the counterparty, and vice versa, the Company also has the right to require

the counterparty to sell the tendered shares to the Company, all in accordance with the terms of the option framework agreement and the related Master Put/Call Agreement.

The Master Put/Call Agreement grants to the counterparty thereto the option to require the Company to purchase, and grants to the Company the option to require the counterparty to sell the Company’s ordinary shares owned by the counterparty in consideration of the payment by the Company to the counterparty of an amount in cash, which may include a premium over the price paid by such counterparty for such shares. Each Master Put/Call Agreement permits multiple exercises of the options granted pursuant to it. Each Master Put/Call Agreement may be used in connection with transactions described in the previous paragraph and related transactions.

All forms of the contract provide that the counterparty will purchase the shares as principal and sell any shares purchased to the Company, in order to comply with the requirements of the Act.

A list of counterparties is annexed to the forms of share repurchase contract. The counterparties are banks, investment banks and/or brokers. If the directors determine that ordinary shares should be repurchased, one or more of the counterparties would be chosen to acquire shares and sell them on to the Company in accordance with the terms of one or more repurchase contracts in the form approved.

Under the Act, any shares owned by the counterparty pursuant to the Master Put/Call Agreements and the forms of share repurchase contract being voted upon cannot be counted towards determining whether the resolution approving the Master Put/Call Agreements and the forms of share repurchase contract has been passed.

Approval of the forms of contract and counterparties are not an approval of any specific share repurchase transaction. As the directors are committed to managing the Company’s capital effectively, the directors will determine, within the limits set forth by the authorisation and in accordance with applicable law, the manner, timing and conditions, including amounts involved, of any share repurchases by establishing specific share repurchase programs authorizations, which may include Rule 10b5-1 and/or Rule 10b-18 repurchases, accelerated share repurchases, tender offers and/or related repurchases under Master Put/Call Agreements. Any such share repurchases will depend on a variety of elements, including the Company’s business plans, financial performance and market conditions, and will be subject to applicable corporate laws, securities laws and stock exchange rules. There can be no assurance as to whether the Company will repurchase any of its shares or as to the amount of any such repurchases or the prices at which such repurchases may be made, subject to the limitations set out in the resolution and summarised above. The directors will exercise this authority only where they consider that such purchases will be in the best interests of the Company and its shareholders.

The authority conferred by Resolution 21 will expire at the end of the next annual general meeting or, if sooner, on 12 November 2026.

As required by the Act, the forms of the share repurchase contract and the list of proposed counterparties will be available for inspection by members of the Company at the registered office of the Company. Please refer to note 2 of the Notes to the Notice of AGM for further details.